```html

Quinidine‑Induced Myocarditis: A Comprehensive Medical Guide

Overview

Quinidine‑induced myocarditis is an inflammatory condition of the heart muscle that occurs as an adverse reaction to quinidine, a class Ia anti‑arrhythmic drug historically used to treat atrial fibrillation, ventricular tachycardia, and certain types of supraventricular tachycardia. The inflammation can impair the heart’s ability to contract and conduct electrical signals, leading to symptoms ranging from mild fatigue to life‑threatening heart failure.

• Who it affects: Primarily adults receiving quinidine for rhythm control, but cases have been reported in older children and adolescents on off‑label therapy.
• Prevalence: Myocarditis is a rare drug reaction. Large pharmacovigilance databases (e.g., FDA Adverse Event Reporting System) show ≈ 1–3 cases per 10,000 patients exposed to quinidine, with higher rates in patients with pre‑existing cardiac disease or hypersensitivity. Because quinidine use has declined in many countries, recent incidence is likely lower than historical reports.
• Typical timeline: Symptoms usually appear 1 – 4 weeks after starting quinidine, but delayed presentations up to 3 months have been documented.

Understanding this condition is crucial because early recognition and removal of the offending drug can prevent permanent damage.

Symptoms

Symptoms reflect both myocardial inflammation and resulting cardiac dysfunction. Not all patients will have every symptom.

General/Constitutional

• Fatigue or weakness – often progressive.
• Low‑grade fever – may be intermittent.
• Myalgias or arthralgias – part of a systemic hypersensitivity reaction.
• Weight loss – from reduced appetite.

Cardiac‑Specific

• Chest pain – typically dull or pleuritic; may improve when leaning forward.
• Palpitations – new or worsening irregular beats.
• Dyspnea – shortness of breath on exertion progressing to rest.
• Orthopnea & paroxysmal nocturnal dyspnea – signs of left‑sided heart failure.
• Peripheral edema – swelling of ankles/feet.
• Syncope or presyncope – due to arrhythmias or low cardiac output.
• Heart murmur or new S3 gallop – detected on auscultation.

Systemic Signs Suggesting a Hypersensitivity Component

• Rash (maculopapular or urticarial).
• Eosinophilia on blood count.
• Liver enzyme elevation.

Causes and Risk Factors

Primary Cause

Quinidine itself is the trigger. The exact pathophysiology is not fully understood, but two mechanisms dominate:

1. Direct toxic injury – Quinidine metabolites may generate oxidative stress within myocytes.
2. Immune‑mediated hypersensitivity – The drug can act as a hapten, prompting an eosinophilic infiltrate (eosinophilic myocarditis) which is a recognized pattern of drug‑induced myocarditis.

Key Risk Factors

• Higher quinidine doses (≥ 600 mg/day) or rapid dose escalation.
• Pre‑existing cardiac disease (e.g., coronary artery disease, prior myocarditis, cardiomyopathy).
• Allergic predisposition – prior drug rash, asthma, or eosinophilia.
• Renal or hepatic impairment – reduced clearance leading to higher plasma concentrations.
• Concomitant use of other cardiotoxic agents – e.g., amiodarone, certain chemotherapy drugs.
• Genetic factors – polymorphisms in cytochrome P450 enzymes (CYP3A4/5) that affect quinidine metabolism.

Diagnosis

Diagnosing quinidine‑induced myocarditis requires a high index of suspicion because symptoms overlap with many cardiac and non‑cardiac conditions.

Step‑by‑step diagnostic approach

1. Clinical assessment – detailed medication history (including start date and dose), symptom chronology, and physical examination.
2. Baseline laboratory tests:
   • Complete blood count (look for eosinophilia).
   • Cardiac biomarkers: troponin I/T (often mildly elevated) and CK‑MB.
   • Inflammatory markers: ESR, CRP.
   • Liver & kidney function tests.
3. Electrocardiogram (ECG) – may show new ST‑T changes, low voltage QRS, or arrhythmias.
4. Echocardiography – first‑line imaging to assess left ventricular ejection fraction (LVEF), wall motion abnormalities, and pericardial effusion.
5. Cardiac magnetic resonance imaging (CMR) – the gold standard for non‑invasive myocarditis diagnosis. Look for:
   • Myocardial edema (T2‑weighted imaging).
   • Late gadolinium enhancement (LGE) in a non‑ischemic pattern.
   • Eosinophilic infiltration appears as subepicardial LGE.
6. Endomyocardial biopsy (EMB) – reserved for cases where diagnosis remains uncertain or when the patient is deteriorating despite drug withdrawal. Histology typically reveals lymphocytic or eosinophilic infiltrates with myocyte necrosis.
7. Drug rechallenge – rarely performed; a positive rechallenge (return of symptoms after re‑exposure) confirms causality but is unsafe and therefore omitted in clinical practice.

Diagnostic criteria commonly follow the “Lake Louise Criteria” for CMR and the “European Society of Cardiology (ESC) myocarditis guideline” recommendations.

Treatment Options

Treatment is two‑pronged: stop the offending drug and manage the inflammatory process and its cardiac consequences.

1. Immediate Measures

• Discontinue quinidine – This is the most critical step. Transition to an alternative anti‑arrhythmic (e.g., flecainide, sotalol) under cardiology guidance.
• Supportive cardiac care – Supplemental oxygen, diuretics for volume overload, and low‑dose beta‑blockers if tachyarrhythmias persist.

2. Anti‑inflammatory Therapy

• Corticosteroids – Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then taper based on clinical response and repeat imaging. Steroids are especially beneficial in eosinophilic myocarditis.
• Colchicine – 0.5 mg twice daily can be added for its anti‑inflammatory effect and to reduce pericardial involvement.
• Immunosuppressive agents (e.g., azathioprine, mycophenolate) – Considered only if myocarditis persists despite steroids and in the absence of active infection.

3. Heart‑Failure Directed Therapies

• ACE inhibitors or ARBs.
• Beta‑blockers (once hemodynamics are stable).
• Mineralocorticoid receptor antagonists (e.g., spironolactone).
• Diuretics for congestion.
• In severe cases, mechanical circulatory support** (intra‑aortic balloon pump, ECMO) may be required.

4. Arrhythmia Management

• Temporary pacing for high‑grade AV block.
• Implantable cardioverter‑defibrillator (ICD) if ventricular arrhythmias persist after recovery.

5. Follow‑up Imaging

Repeat echocardiogram at 2–4 weeks and CMR at 3–6 months to document resolution of inflammation and recovery of function.

Living with Quinidine‑Induced Myocarditis

Recovery can be gradual; most patients regain normal cardiac function within 3–6 months if treatment is prompt.

Daily Management Tips

• Medication adherence – Take prescribed steroids and heart‑failure meds exactly as directed.
• Monitor weight – A sudden gain of > 2 kg in one day may indicate fluid retention; report to your provider.
• Track symptoms – Keep a diary of breathlessness, palpitations, and chest discomfort.
• Limit strenuous activity – Follow a cardiology‑approved exercise plan; avoid high‑intensity workouts until cleared.
• Vaccinations – Annual flu vaccine and COVID‑19 boosters reduce the risk of viral infections that could stress the heart.
• Hydration & low‑salt diet – Helps control blood pressure and prevents edema.
• Regular follow‑up – Cardiology visits every 1–3 months initially, then spaced out as stability is documented.

Prevention

Because the condition is drug‑related, primary prevention centers on prescription practices.

• Risk‑stratified prescribing – Reserve quinidine for patients with clear indications and no alternative agents.
• Start low, go slow – Initiate at the lowest effective dose and titrate cautiously.
• Baseline screening – Obtain baseline ECG, echocardiogram, CBC with differential, and liver/kidney labs before starting quinidine.
• Early monitoring – Repeat labs (CBC with eosinophil count, troponin, renal function) at 1‑week and 4‑week intervals after initiation.
• Patient education – Inform patients to report fever, rash, new chest pain, or worsening dyspnea immediately.
• Alternative agents – Consider other anti‑arrhythmics (e.g., dofetilide, propafenone) or non‑pharmacologic options such as catheter ablation when appropriate.

Complications

If untreated or delayed, quinidine‑induced myocarditis can lead to serious outcomes:

• Persistent left ventricular dysfunction – May progress to dilated cardiomyopathy.
• Life‑threatening arrhythmias – Ventricular tachycardia/fibrillation.
• Heart failure – Requiring hospital admission, inotropes, or transplant.
• Thromboembolic events – Stasis in a poorly contracting ventricle can cause clot formation.
• Sudden cardiac death – Most severe but preventable with early detection.

When to Seek Emergency Care

References

• Mayo Clinic. “Drug‑induced myocarditis.” Updated 2023. https://www.mayoclinic.org
• American Heart Association. “Myocarditis: Diagnosis and Management.” 2022 scientific statement.
• European Society of Cardiology. “2022 ESC Guidelines for the management of myocarditis.” https://www.escardio.org
• FDA Adverse Event Reporting System (FAERS). Quinidine‑associated myocarditis reports, 2000‑2023.
• Centers for Disease Control and Prevention. “Understanding Heart Failure.” 2024.
• Cleveland Clinic. “Eosinophilic myocarditis: clinical features and treatment.” 2023.

```